Cell cycle arrest in human HepG2 cells transfected with p53 siRNA assessed as accumulation at S-phase after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 20.37 to 22.8%)
Induction of apoptosis in human HepG2 cells transfected with p53 siRNA assessed as early apoptotic cells after 24 hrs by Annexin V-FITC/ propidium iodide staining based flow cytometry (Rvb = 5.99 to 6.01%)
Antitumor activity against human NCI-H460 cells xenografted in Balb/c nude mouse assessed as relative tumor volume increment rate at 50 mg/kg, ip bid for 13 days measured on day 14 post last dose relative to control
Antitumor activity against human NCI-H460 cells xenografted in Balb/c nude mouse assessed as relative tumor volume increment rate at 25 mg/kg, ip bid for 13 days measured on day 14 post last dose relative to control
Antitumor activity against human NCI-H460 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 25 mg/kg, ip bid for 13 days measured on day 14 post last dose relative to control
Antitumor activity against human NCI-H460 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 50 mg/kg, ip bid for 13 days measured on day 14 post last dose relative to control
Antitumor activity against human NCI-H460 cells xenografted in Balb/c nude mouse assessed as induction of necrosis at 25 to 50 mg/kg, ip bid for 13 days measured on day 14 post last dose by hematoxylin and eosin staining based microscopic method
Antitumor activity against human Bel7404 cells xenografted in Balb/c nude mouse assessed as induction of necrosis at 25 to 50 mg/kg, ip for 20 days measured on day 21 post last dose by hematoxylin and eosin staining based microscopic method
Cell cycle arrest in human HepG2 cells assessed as accumulation at G1-phase at 6 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 50.47%)